We are pleased to introduce Hydrix Medical, a member of the Hydrix Group. Hydrix Medical has been established to support our expansion into the marketing and distribution of cardiovascular products and technologies in the Asia-Pacific market. The first of these products will be the AngelMed Guardian.
On 13 March 2020, Hydrix announced it had been granted the exclusive rights by Angel Medical Systems to distribute its AngelMed Guardian, an implantable monitoring device that can detect Acute Coronary Syndrome (ACS) events, including silent heart attacks. This is particularly beneficial as approximately fifty percent of all heart attacks have either no symptoms (silent) or have atypical symptoms that are often ignored or go unrecognized. Hydrix’s distribution rights cover eight Asia-Pacific countries in which over 700,000 people suffer an ACS event each year.
The Hydrix Medical team, supported by the new website, is actively engaging in market development efforts for the AngelMed Guardian and other future medical technology products.
Please take a moment to explore our new webpage.
